Stonegate Capital Partners has announced the initiation of coverage on AB Science S.A. (ENXTPA: AB), a late-stage biotechnology company focused on developing masitinib, an oral, selective tyrosine kinase inhibitor designed to modulate maladaptive neuroinflammation through mast-cell and microglia/macrophage pathways. The coverage initiation, announced on February 10, 2026, underscores the potential of AB Science's pipeline, particularly its lead asset masitinib, which is being positioned as an add-on therapy across amyotrophic lateral sclerosis (ALS), progressive multiple sclerosis (MS), and Alzheimer's disease (AD).
The announcement is significant because it brings attention to a company with a promising drug candidate that could address high unmet medical needs in neurodegenerative diseases. For ALS, masitinib is supported by prior Phase 2b/3 data, which showed encouraging results in slowing disease progression. The Phase 3 trial for progressive MS has been authorized in the United States and 12 European Union countries, with approximately 94 sites initiating. This broad authorization indicates regulatory confidence and a robust clinical development plan. Additionally, AB Science maintains earlier-stage upside through its second asset, AB8939, in acute myeloid leukemia (AML).
Stonegate Capital Partners highlighted the combination of a treatment for ALS along with the optionality from the rest of the company's portfolio as reasons for excitement. The firm noted that financing is supported by grants, which may reduce dilution risk for shareholders. The coverage initiation could increase visibility and investor interest in AB Science, potentially impacting its stock price and ability to secure partnerships or additional funding.
For more details, the full announcement is available here. Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Its affiliate, Stonegate Capital Markets (member FINRA), offers a full spectrum of investment banking services.
The initiation of coverage by a reputable research firm like Stonegate suggests that AB Science's masitinib program is gaining traction and could represent a significant opportunity for investors. As the company progresses its clinical trials, the outcomes will be closely watched by the medical community and investors alike.
